Palmitoylethanolamide (Normast®) in chronic neuropathic pain by compressive type lumbosciatalgia: Multicentric clinical study;La palmitoiletanolamida (Normast®) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: Estudio clínico multicéntrico

DOLOR

Volumn 25, Issue 1, 2010, Pages 35-42

  Guida, G ^a   De Martino, M ^b   De Fabiani, A ^c   Cantieri, L ^d   Alexandre, A ^e   Vassallo, G M ^f   Rogai, M ^g   Lanaia, F ^h   Petrosino, S ⁱ  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Hospital Santa Maria Della Speranza Battipaglia   (Italy)

^c Bollate Hospital   (Italy)

^d Hospital de Montebelluna   (Italy)

^e Castelfranco Veneto Hospital   (Italy)

^f Instituto de Medicina Deportiva   (Italy)

^g Hospital de Recco   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ Hospital de Pescopagano   (Italy)

Author keywords

Chronic neuropathy pain; Lumbosciatic algias; Palmitoylethanolamide

Indexed keywords

NORMAST; PALMIDROL; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVERTEBRAL DISK DEGENERATION; ISCHIALGIA; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE COMPRESSION; NEUROPATHIC PAIN; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCIATIC NERVE; TREATMENT DURATION; VISUAL ANALOG SCALE;

EID: 77953103422     PISSN: 02140659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Zhukov OD. Distribution of N-([1-14C]-palmitoyl) ethanolamide in rat tissues. Ukr Biokhim Zh. 1999;71(4):124-125
2. Epps DE, Schmid PC, Natarajan V, Schimid HHO. N-acylethanolamine accumulation in infracted myocardium. Biochem Biophys Res Commun. 1979;90:628-633
3. Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, Schid HHO. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 1995;375:117-220.
4. Kondo S, Sugiura T, Kodaka T, Kudo N, Waku K, Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamine) in cadmium chloride-administrated rat testis. Arch Blochem Biophys. 1998;354:303-310 (Pubitemid 28373981)
5. Hansen HS, Moesgaard B, Hensen HH. N-acylethanolamines and precursor phospholipids relation to cell injury. Chem Phys Lipids. 2000;108:135-150
6. Petrosino S, Palazzo E, De Novellis V, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52:415-422 (Pubitemid 46127787)
7. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature (London). 1998;394:227-281 (Pubitemid 28335039)
8. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur J Pharmacol. 2001;419:191-198 (Pubitemid 32568218)
9. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem. 2002;9:663-674
10. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin- induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci. 2003;73(18):2345-2353
11. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hiperalgesic affects in a murine model of neuropathic pain: involvement of CB (1), TRPV1 and PPAR gamma receptors and neurotrophic factors. Pain. 2008;139:541-550
12. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39 Spec No: 145-147
13. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 1995;92(6):3376-3380
14. De Filippis D, D'Amico A, Iuvone T. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. J Neuroendocrinol. 2008;20 Suppl 1:20-25 (Pubitemid 351552672)
15. Kinet JP. The essential role of mast cells in orchestrating inflammation. Immunol Rev. 2007;217:5-7. (Pubitemid 46718159)
16. Olsson Y. Mast cells in the nervous system. Int Rev Cytol. 1968;24:27-70.
17. Lundborg G, Myers R, Powell H. Nerve compression injury and increased endoneural fluid pressure: a "miniature compartment syndrome". J Neurol Neurosurg Psychiatry. 1983;46(12):1119-1124
18. Lundborg G. Intraneural microcirculation. Orthop Clin North Am. 1988;19(1):1-12.
19. Powell HC, Costello ML, Myers RR. Galactose neuropathy. Permeability studies, mechanism of edema, and mast cell abnormalities. Acta Neuropathol. 1981;55(2):89-95.
20. Nicol GD, Vasko MR. Unravelling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks? Mol Interv. 2007;7(1):26-41.
21. Leon A, Buriani A, Dal Toso R, Romanello S, Aloe L, Levi-Montalcini R. Mast cells synthesize, store and release nerve growth factor. Proc Nat Acad Sci USA. 1994;91(9):3739-3743 (Pubitemid 24139507)
22. Carlson SL, Johnson S, Parrish ME, Cass WA. Development of immune hyperinnervation in NGF-transgenic mice. Exp Neurol. 1998; 149(1):209-220 (Pubitemid 28091030)
23. Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther. 2008;326(1):12-23. (Pubitemid 351872139)
24. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404(6773):84-87 (Pubitemid 30143137)
25. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASE J. 2001;15:300-302
26. Loria F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci. 2008;28(4):633-641
27. Schomacher M, Müller HD, Schwab S, Sommer C, Schäbitz WR. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res. 2008. Epub ahead of print.
28. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N-(2 hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur J Pharmacol. 1996;300(3):227-236 (Pubitemid 26144798)
29. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002;135(1):181-187 (Pubitemid 34102111)
30. Knavel EM, Thielen KR, Kallmes DF. Vertebroplasty for the treatment of traumatic nonosteoporotic compression fractures. AJNR Am J Neuroradiol. 2008. Epub ahead of print.
31. Conigliaro R, Drago V, Foster PS. Use of the palmitoylethanolamide in the entrapment neuropathy of the median in the wrist (CTS) [manoscritto in preparazione].
32. Paganelli A, Murina F, Radici G. L'utilizzo di un preparato a base della vulvodinia localizzata (vestibulodinia): studio pilota. Atti della Società Italiana di Ginecologia e Ostetricia, 48° edizione; 2007; Napoli.
33. Jergová S, Cízková D. Microglial activation in different models of peripheral nerve of the rat. J Mol Histol. 2007;38(3):245-251 (Pubitemid 46980558)
34. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478-486 (Pubitemid 351733419)
35. Horvath G, Kekesi G, Nagy E, Benedek G. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain. 2008;134:277-284
36. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol. 2007;150(4):519-525 (Pubitemid 46280648)
37. Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. Mast cell-derivated histamine mediates cystitis pain. PLoS ONE. 2008;3(5):2096.
38. Theoharides TC, Kempuraj D, Iliopoulou BP. Mast cells, T cells an inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol. 2007;601:423-430